Enanta Pharmaceuticals | ENTA - Cash And Equivalent


Enanta Pharmaceuticals reported $37.44M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Amgen USD 9.13B 316M Dec/2025
Anika Therapeutics USD 57.99M 4.82M Sep/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
BioCryst Pharmaceuticals USD 84.08M 3.95M Sep/2025
Biogen USD 3.01B 854.3M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Immunic USD 35.13M 20.18M Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
Insmed USD 510.44M 175.68M Dec/2025
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
J&J USD 19.71B 1.48B Dec/2025
Karyopharm Therapeutics USD 37.67M 1.05M Sep/2025
Ligand Pharmaceuticals USD 174.93M 489.59M Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Novavax USD 268.02M 14.28M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025